{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:29:55Z","timestamp":1781818195501,"version":"3.54.5"},"update-to":[{"DOI":"10.1002\/14651858.cd002819","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2007,1,24]],"date-time":"2007-01-24T00:00:00Z","timestamp":1169596800000}}],"reference-count":117,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002819.pub2","type":"journal-article","created":{"date-parts":[[2007,1,25]],"date-time":"2007-01-25T08:35:23Z","timestamp":1169714123000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Cyclophosphamide for multiple sclerosis"],"prefix":"10.1002","volume":"2009","author":[{"given":"Loredana","family":"La Mantia","sequence":"first","affiliation":[{"name":"Fondazione I.R.C.C.S. - Istituto Neurologico C. Besta; MS Group; Via Celoria, 11 Milano Italy 20133"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Milanese","sequence":"additional","affiliation":[{"name":"Fondazione I.R.C.C.S. - Istituto Neurologico C. Besta; MS Group; Via Celoria, 11 Milano Italy 20133"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerina","family":"Mascoli","sequence":"additional","affiliation":[{"name":"Fondazione I.R.C.C.S. - Istituto Neurologico C. Besta; MS Group; Via Celoria, 11 Milano Italy 20133"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"D'Amico","sequence":"additional","affiliation":[{"name":"University of Modena and Reggio Emilia; Department of Oncology and Hematology; Via del Pozzo 71 Modena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Weinstock-Guttman","sequence":"additional","affiliation":[{"name":"The Jacobs Neurological Institute, State University of New York at Buffalo; Baird MS Center; 100 High Street Buffalo New York USA 14203"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,1,24]]},"reference":[{"key":"10.1002\/14651858.CD002819.pub2-BIB0001|cit1","first-page":"239","article-title":"Immunosuppression for multiple sclerosis (Letter) [comment on: N Engl J Med 1983; 308: 173-80]","volume":"309","author":"Fishbeck","year":"1983","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0002|cit2","first-page":"A78","article-title":"Controlled randomized trial of high-dose cyclophosphamide, plasmapheresis and ACTH in progressive multiple sclerosis (Abstract)","volume":"32","author":"Hauser","year":"1982","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/archneur.1983.04050100027009","article-title":"Immunosuppression and plasmapheresis in chronic progressive multiple sclerosis. Design of a clinical trial","volume":"40","author":"Hauser","year":"1983","journal-title":"Archives of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD002819.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1056\/NEJM198301273080401","article-title":"Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange and ACTH [comment in: N Engl J Med 1983; 309: 239-40; comment in: N Engl J Med 1983; 309: 241; comment in: Lancet 1991; 337:1540-1]","volume":"308","author":"Hauser","year":"1983","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0005|cit5","first-page":"241","article-title":"immunosuppression for multiple sclerosis (Letter) [Comment on: N Engl J Med 1983; 308: 173-80]","volume":"309","author":"Hauser","year":"1983","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0006|cit6","first-page":"239","article-title":"Immunosuppression for multiple sclerosis (Letter) [Comment on: N Engl J Med 1983: 308: 173-80]","volume":"309","author":"Miller","year":"1983","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/0140-6736(91)93226-Y","article-title":"Cyclophosphamide in multiple sclerosis (Letter) [Comment on: N Engl J Med 1983; 308: 173-80]","volume":"337","author":"Noseworthy","year":"1991","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0008|cit8","first-page":"239","article-title":"Immunosuppression for multiple sclerosis (Letter) [Comment on: N Engl J Med 1983; 308: 173-80]","volume":"309","author":"Utermohlen","year":"1983","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0011|cit9","first-page":"14","article-title":"Experience with cyclophosphamide in multiple sclerosis: The cons","volume":"38 Suppl 2","author":"Likosky","year":"1988","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0009|cit10","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1136\/jnnp.54.12.1055","article-title":"Intensive immunosuppression in chronic progressive multiple sclerosis: the kaiser study","volume":"54","author":"Likosky","year":"1991","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0010|cit11","first-page":"108","article-title":"Intensive cyclophosphamide immunosuppression in multiple sclerosis: a randomized blinded multicenter clinical trial (Abstract)","volume":"37 Suppl 1","author":"Likosky","year":"1987","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0012|cit12","first-page":"241","article-title":"The cost effectiveness evaluation of the Canadian cooperative study of cyclophosphamide and plasma exchange in Multiple Sclerosis (abstract)","volume":"17","author":"Bullas","year":"1990","journal-title":"Le Journal Canadien Des Sciences Neurologiques"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0013|cit13","first-page":"1034","article-title":"Cyclophosphamide and plasma exchange in multiple sclerosis (comment on Lancet 1991; 337:441-6)","volume":"337","author":"Currier","year":"1991","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/0140-6736(91)92688-X","article-title":"Cyclophosphamide and plasma exchange in multiple sclerosis (letter) Comments to Lancet 1991; 337: 441-446)","volume":"337","author":"Khatri","year":"1991","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0015|cit15","first-page":"579","article-title":"Cyclophosphamide and multiple sclerosis (letter)","volume":"44","author":"Noseworht","year":"1994","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.44.1.16","article-title":"The impact of blinding on the resulkts of a randomized, placebo controlled multiple sclerosis clinical trial","volume":"44","author":"Noseworthy","year":"1994","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/0140-6736(91)93226-Y","article-title":"Cyclophosphamide and plasma exchange in multiple sclerosis [comments on The Lancet 1991; 337:441-6]","volume":"337","author":"Noseworthy","year":"1991","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1212\/WNL.39.4.605-a","article-title":"Acceptance of placebo controlled trial design by progressive multiple sclerosis patients","volume":"39","author":"Noseworthy","year":"1989","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1212\/WNL.40.6.971","article-title":"Interrater variability with the expanded disability status scale (EDSS) and functional systems (FS) in a multiple sclerosis trial","volume":"40","author":"Noseworthy","year":"1990","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0140-6736(91)93226-Y","article-title":"The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis","volume":"337","author":"Noseworthy","year":"1991","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0021|cit21","first-page":"1033","article-title":"Cyclophosphamide and plasma exchange in multiple sclerosis (letter) [comment on Lancet 1991; 337:441-446]","volume":"337","author":"Weiner","year":"1991","journal-title":"The Lancet"},{"issue":"5","key":"10.1002\/14651858.CD002819.pub2-BIB0022|cit22","first-page":"399","article-title":"Early results of the treatment of chronic progressive forms of multiple sclerosis with cyclophosphamide and ACTH","volume":"22","author":"Wender","year":"1988","journal-title":"Neur Neurochir Pol"},{"issue":"3","key":"10.1002\/14651858.CD002819.pub2-BIB0023|cit23","first-page":"188","article-title":"Late results of the treatment of the chronic progressive form of multiple sclerosis with cyclophosphamide and ACTH","volume":"23","author":"Wender","year":"1989","journal-title":"Neurologia i Neurochirurgia Polska"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0024|cit24","first-page":"345","article-title":"Multiple sclerosis and autoimmunisation. Treatment with anti-neoplastic drugs","volume":"215","author":"Aimard","year":"1966","journal-title":"Lyon Medical"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1749-6632.1988.tb27163.x","article-title":"Cumulative experience with high-dose intravenous CFX and ACTH therapy in chronic progressive multiple sclerosis","volume":"540","author":"Carter","year":"1988","journal-title":"Annals of New York Academy Sciences"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD002819.pub2-BIB0026|cit26","first-page":"264","article-title":"Five year Experience with Intensive Immunosuppression in progressive Multiple Sclerosis using high-dose IV Cyclophosphamide plus ACTH ( Abstract)","volume":"36","author":"Carter","year":"1986","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0027|cit27","first-page":"9","article-title":"Immunosuppression with high-dose IV CFX and ACTH in progressive MS: cumulative 6-year experience in 164 patients","volume":"38 Suppl 2","author":"Carter","year":"1988","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD002819.pub2-BIB0028|cit28","first-page":"88","article-title":"Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophsophamide and monoclonal antibodies (comments)","volume":"57","author":"Dawson","year":"1987","journal-title":"Rivista di Neurologia"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0029|cit29","first-page":"209","article-title":"Combined therapeutic trial in multiple sclerosis: hydrocortisone hemisuccinate with cyclophosphamide or cytosine arabinoside","volume":"73","author":"Cendrowski","year":"1973","journal-title":"Acta Neurologica Belgica"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF02333857","article-title":"Ciclophosphamide in remitting relapsing multiple sclerosis","volume":"11","author":"D'Andrea","year":"1990","journal-title":"Italian Journal of Neurological Sciences"},{"issue":"3","key":"10.1002\/14651858.CD002819.pub2-BIB0031|cit31","first-page":"119","article-title":"Clinical study with intravenous boluses of cyclophosphamide in relapsing-remitting multiple sclerosis","volume":"37","author":"D'Andrea","year":"1991","journal-title":"Rivista di Neurobiologia."},{"issue":"6-7","key":"10.1002\/14651858.CD002819.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0035-3787(04)71015-2","article-title":"Treatment of progressive multiple sclerosis with monthly pulsed cyclophosphamide-methylprednisolone: predictive factors of treatment response","volume":"160","author":"Delmont","year":"2004","journal-title":"Revue Neurologique"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1136\/jnnp.38.6.592","article-title":"Cyclophosphamide in exacerbations of multiple sclerosis: therapeutic trial and a strategy for pilot drug studies","volume":"38","author":"Drachman","year":"1975","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0034|cit34","unstructured":"Gauthier A Bharanidharan P Stazzone L Smith DR Dawson DM Hafler DA Treatment of relapsing remitting interferon\/glatiramer acetate unresponsive patients with pulse cyclophosphamide Ame. Acad Neurology 55th Annual Meeting (Abstract) Neurology 2003 A148"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0035|cit35","first-page":"967","article-title":"Les immunodepresseurs en neurologie","volume":"75","author":"Girard","year":"1967","journal-title":"Medycyna Pracy"},{"issue":"10","key":"10.1002\/14651858.CD002819.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1001\/archneur.63.10.noc60076","article-title":"High-dose cyclophsophamide for moderate to severe refractory multiple sclerosis","volume":"63","author":"Gladstone","year":"2006","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0165-5728(99)00039-9","article-title":"Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis","volume":"99","author":"Gobbini","year":"1999","journal-title":"Journal of Neuroimmunology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00316148","article-title":"Intensive immunosuppression with cyclophosphamode in multiple sclerosis. Follow-up of 110 patients for 2-6 years","volume":"214","author":"Gonsette","year":"1977","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/archneur.1987.00520200027013","article-title":"Cyclophosphamide in chronic progressive multiple sclerosis: maintenance versus Nonmaintenance therapy","volume":"44","author":"Goodkin","year":"1987","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0040|cit40","first-page":"184","article-title":"Cyclophosphamide in chronic progressive multiple sclerosis: maintenance versus non-maintenance therapy (Abstract)","volume":"36 Suppl 1","author":"Goodkin","year":"1986","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0041|cit41","first-page":"1955","article-title":"Immunosuppressive therapy of multiple sclerosis usign cyclophosphamide and imuran. Report on 57 cases","volume":"27","author":"Gopel","year":"1972","journal-title":"Das Deutsche Gesundheitswesen"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0042|cit42","first-page":"289","article-title":"Monthly intravenous cyclophosphamide for MS works, but it doesn't last (abstract)","volume":"37 Suppl 1","author":"Haerer","year":"1987","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0043|cit43","first-page":"256","article-title":"Pilot study of 3 years evaluating pulse cyclophosphamide and methylprednisolone versus methylprednisolone (abstract)","volume":"32","author":"Hohol","year":"1992","journal-title":"Annals of neurology."},{"key":"10.1002\/14651858.CD002819.pub2-BIB0044|cit44","first-page":"403","article-title":"Treatment of progressive multiple sclerosis with pulse cyclophosphamide\/methylprednisolone: response to therapy linked to the duration of progressive disease","volume":"5","author":"Hohol","year":"1999","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0303-8467(75)80007-2","article-title":"Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone","volume":"78","author":"Hommes","year":"1975","journal-title":"Clinical Neurology and Neurosurgery"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF00313182","article-title":"Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis","volume":"223","author":"Hommes","year":"1980","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0047|cit47","first-page":"239","article-title":"Immunosuppression for multiple sclerosis (Letter) [comment on: N Engl J Med 1983; 308: 173-80]","volume":"309","author":"Huston","year":"1983","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/135245850100700309","article-title":"Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to convemtional therapy","volume":"7","author":"Khan","year":"2001","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1001\/archneur.1984.04050180056018","article-title":"Plasmapheresis with immunosuppressive drug therapy in progressive multiple sclerosis. A pilot study","volume":"41","author":"Khatri","year":"1984","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1749-6632.1984.tb14810.x","article-title":"Plasmapheresis and combined immunosuppressive drug therapy in chronic progressive multiple sclerosis. Chosing the patient who should respond","volume":"436","author":"Khatri","year":"1984","journal-title":"Annals of the New York Academy of Sciences."},{"key":"10.1002\/14651858.CD002819.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1212\/WNL.35.3.312","article-title":"Chronic progressive multiple sclerosis: double-blind controlled study of plasma pheresis in patients taking immunosuppressive drugs","volume":"35","author":"Khatri","year":"1985","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0053|cit52","first-page":"50","article-title":"Experience with use of plasmapheresis in chronic progressive multiple sclerosis: the pros","volume":"38 Suppl 2","author":"Khatri","year":"1988","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0052|cit53","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1212\/WNL.41.3.409","article-title":"Plasma exchange in chronic progressive multiple sclerosis. A long term study","volume":"41","author":"Khatri","year":"1991","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1001\/archneur.1988.00520250033014","article-title":"Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis","volume":"45","author":"Killian","year":"1988","journal-title":"Archives of Neurology"},{"issue":"46","key":"10.1002\/14651858.CD002819.pub2-BIB0055|cit55","first-page":"111","article-title":"Immunosuppressive Cyclophosphamide-Therapy for multiple sclerosis","volume":"111","author":"Kornhuber","year":"1986","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"13","key":"10.1002\/14651858.CD002819.pub2-BIB0056|cit56","first-page":"330","article-title":"Risk of malignancies of cyclophosphamide therapy in multiple sclerosis","volume":"112","author":"Kornhuber","year":"1987","journal-title":"Deutsche Medizinische Wochenschrift"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0057|cit57","first-page":"S85","article-title":"The efficacy of different cyclophosphamide treatment schedules in progressive multiple sclerosis patients (Abstract)","volume":"244","author":"Mantia","year":"1997","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/BF03028809","article-title":"Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study","volume":"19","author":"Mantia","year":"1998","journal-title":"Italian Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0059|cit59","first-page":"147","article-title":"Oral cyclophosphamide treatment in multiple sclerosis","volume-title":"Recent advances in multiple sclerosis therapy","author":"Laterre","year":"1989"},{"issue":"3","key":"10.1002\/14651858.CD002819.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1191\/135248506ms1275oa","article-title":"Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue","volume":"12","author":"Lebrun","year":"2006","journal-title":"Multiple Sclerosis"},{"issue":"1","key":"10.1002\/14651858.CD002819.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1212\/WNL.57.1.62","article-title":"Autologous hematopoietic stem cell transplantation suppress Gd-enhanced MRI activity in MS","volume":"57","author":"Mancardi","year":"2001","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD002819.pub2-BIB0062|cit62","first-page":"20","article-title":"Clinico-laboratory study of methylprednisolone and cyclophosphamide tretament in patients with multiple sclerosis relapse","volume":"42","author":"Manova","year":"2000","journal-title":"Folia Medica"},{"issue":"3","key":"10.1002\/14651858.CD002819.pub2-BIB0063|cit63","first-page":"5","article-title":"Clinico-electrophysiological correlates in patients with relpsing remitting multiple sclerosis","volume":"43","author":"Manova","year":"2001","journal-title":"Folia Medica"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF00450997","article-title":"Effective treatment of chronically progressive multiple sclerosis with low dose cyclophosphamide with minor side effects","volume":"238","author":"Mauch","year":"1989","journal-title":"European Archives of Psychiatry and Neurological Sciences"},{"issue":"2","key":"10.1002\/14651858.CD002819.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1191\/1352458502ms774xx","article-title":"Evaluation of myocardial functional parameters during intravenous cyclophosphamide pulse therapy: a case report","volume":"8","author":"Merico","year":"2002","journal-title":"Mult Scler"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1001\/archneur.1987.00520160013006","article-title":"Correlation of clinical and immunologic states in multiple sclerosis","volume":"44","author":"Mickey","year":"1987","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0140-6736(69)91788-7","article-title":"Cyclophosphamide in multiple sclerosis","volume":"1","author":"Millac","year":"1969","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/BF02337446","article-title":"24-month follow-up of multiple sclerosis patients treated with cyclophosphamide","volume":"11","author":"Millefiorini","year":"1990","journal-title":"Italian Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0070|cit69","first-page":"155","article-title":"The use of cyclophosphamide to treat multiple sclerosis. Review","volume-title":"Clinical Neuropharmacology","volume":"10","author":"Myers","year":"1987"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0069|cit70","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1001\/archneur.1987.00520200032014","article-title":"Cyclophosphamide \"pulses\" in chronic progressive multiple sclerosis. A preliminary clinical trial","volume":"44","author":"Myers","year":"1987","journal-title":"Archives of Neurology"},{"issue":"36","key":"10.1002\/14651858.CD002819.pub2-BIB0071|cit71","first-page":"305","article-title":"The comparison of the effectiveness of tretament of mutliple sclerosis relapse with high-doses of mtehylprednislone, alpha-24 corticotropin and cyclophosphamide","volume":"6","author":"Paradowski","year":"1999","journal-title":"Polski Merkuriusz Lekarski"},{"issue":"3","key":"10.1002\/14651858.CD002819.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/jnnp.71.3.404","article-title":"Combination of cyclophosphamide and interferon beta halst progresison in patients with rapidly transitional sclerosis","volume":"71","author":"Patti","year":"2001","journal-title":"Journal Neurology Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0073|cit73","unstructured":"Patti F Reggio E Fiorilla T Nicoletti A Palermo F Reggio A Rapidly transitional multiple sclerosis patients tretaed with combination of cyclophosphamide and interferon beta: follow up 36 months after discontinuation, 55 Annual meeting March-April 2003 Neurology 2003 A148"},{"issue":"1","key":"10.1002\/14651858.CD002819.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jns.2004.04.023","article-title":"A double blind, placebo-controlled , phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN","volume":"223","author":"Patti","year":"2004","journal-title":"Journal of Neurological Sciences"},{"issue":"12","key":"10.1002\/14651858.CD002819.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1007\/s00415-004-0581-2","article-title":"Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta","volume":"251","author":"Patti","year":"2004","journal-title":"Journal of Neurology"},{"issue":"7","key":"10.1002\/14651858.CD002819.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s00415-003-1089-x","article-title":"Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis","volume":"250","author":"Perini","year":"2003","journal-title":"Journal of Neurology"},{"issue":"8","key":"10.1002\/14651858.CD002819.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1007\/s00415-006-0154-7","article-title":"Mitoxantrone versus cyclophosphamide in secondary- progressive multiple sclerosis: a comparative study","volume":"253","author":"Perini","year":"2006","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1191\/1352458503ms926oa","article-title":"Safety and tolerability of cyclophosphamide ' pulses' in multiple sclerosis: a prospective study in a clinical cohort","volume":"9","author":"Portaccio","year":"2003","journal-title":"Multiple Sclerosis"},{"issue":"10","key":"10.1002\/14651858.CD002819.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00415-005-0857-1","article-title":"The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients. Twenty-four months follow-up","volume":"252","author":"Reggio","year":"2005","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0080|cit80","first-page":"579","article-title":"Tolerability and effectiveness of monthly cyclophosphamide and methylprednisolone pulses in MS patients who deteriorate despite standard therapy (abstract)","volume":"52","author":"Rensel","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0081|cit81","first-page":"221","article-title":"Chronic periodic intravenous cyclophosphamide in progressive multiple sclerosis (Abstract)","volume":"38","author":"Rivera","year":"1988","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3109\/00207459408986012","article-title":"Immunological monitoring and clinical evaluation in cyclophosphamide - treated progressive multiple sclerosis patients","volume":"76","author":"Salmaggi","year":"1994","journal-title":"The International Journal of Neuroscience"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/BF02333666","article-title":"Short-term intensive cyclophosphamide tretament in progressive multiple sclerosis","volume":"8","author":"Siracusa","year":"1987","journal-title":"Italian Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0084|cit84","unstructured":"Smith DR Weinstock-Guttman B Cohen JA Guttman C Wie X Stuart WH Blinded -randomized trial of pulse cyclophosphamide in IFN-beta resistant active MS. American academy of Neurology 55th Annual Meeting (abstract) Neurology 2003 A84"},{"issue":"1","key":"10.1002\/14651858.CD002819.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jns.2004.04.026","article-title":"Preliminary analysis of a trial of pulse cyclophosphamide in IFN-Beta-resistant active MS","volume":"223","author":"Smith","year":"2004","journal-title":"Journal of Neurological Sciences"},{"issue":"5","key":"10.1002\/14651858.CD002819.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1191\/1352458505ms1210oa","article-title":"A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta","volume":"11","author":"Smith","year":"2005","journal-title":"Multiple Sclerosis"},{"issue":"5","key":"10.1002\/14651858.CD002819.pub2-BIB0087|cit87","first-page":"369","article-title":"Intensive immunosuppressive therapy of progressive multiple sclerosis. Results at 3-year follow up of an open study to compare cyclophosphamide alone or combined with plasma exchange and controls","volume":"145","author":"Trouillas","year":"1989","journal-title":"Revue Neurologique"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0088|cit88","first-page":"256","article-title":"Double-blind study of true versus sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis (Abstract)","volume":"38 Suppl 1","author":"Weiner","year":"1988","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0089|cit89","first-page":"283","article-title":"Double-blind study of true vs sham plasmapheresis in patients treated with immunosuppression for acute attacks of multiple sclerosis","volume":"337","author":"Weiner","year":"1990","journal-title":"Progress in clinical and biological research."},{"issue":"9","key":"10.1002\/14651858.CD002819.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.39.9.1143","article-title":"Double-blind study of true versus sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis","volume":"39","author":"Weiner","year":"1989","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1212\/WNL.43.5.910","article-title":"Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis. Final report of the Northeast Cooperative Multiple Sclerosis Tretament Group","volume":"43","author":"Weiner","year":"1993","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/00127893-199705000-00005","article-title":"Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide","volume":"3","author":"Weinstock-Guttman","year":"1997","journal-title":"The Neurologist"},{"issue":"1","key":"10.1002\/14651858.CD002819.pub2-BIB0093|cit93","first-page":"65","article-title":"Treatment of progressive multiple sclerosis with cyclophosphamide","volume":"158","author":"Zephir","year":"2002","journal-title":"Revue Neurologique"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0094|cit94","unstructured":"Zephir H De Seze J Duhamel A Debouverie M Lebrun C Malikova I Treatment of progresive forms of multiple sclerosis by cyclophosphamide . A cohort study of 490 patients. Ame Academy of Neuorlogy . 55 th Annual Meeting (abstract) Neurology 2003 A 148"},{"issue":"1-2","key":"10.1002\/14651858.CD002819.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jns.2003.11.004","article-title":"Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients","volume":"218","author":"Zephir","year":"2004","journal-title":"Journal of Neurological Sciences"},{"issue":"3","key":"10.1002\/14651858.CD002819.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1191\/1352458505ms1172sr","article-title":"One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis","volume":"11","author":"Zephir","year":"2005","journal-title":"Multiple Sclerosis"},{"issue":"8822","key":"10.1002\/14651858.CD002819.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","article-title":"Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis","volume":"340","author":"Boumpas","year":"1992","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0098|cit98","first-page":"1209","article-title":"Antineoplastic agents","volume-title":"Goodman & Gillman's. The pharmacological basis of therapeutics","volume":"II","author":"Calabresi","year":"1991"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0022-5347(01)63185-9","article-title":"Bladder Cancer in patients with multiple sclerosis treated with cyclophosphamide","volume":"159","author":"DeRidder","year":"1998","journal-title":"The Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD002819.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/00003495-199142050-00005","article-title":"Cyclophosphamide toxcicity. Characteristics and avoiding the problems [Review]","volume":"42","author":"Fraiser","year":"1991","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0101|cit101","first-page":"65","article-title":"Clinical practice of immunosuppressive treatments in multiple sclerosis:results of a second international questionnaire","volume":"223","author":"Hommes","year":"2004","journal-title":"Journal of Neruological Sciences"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jada","year":"1996","journal-title":"Controlled Clinical Trials"},{"issue":"11","key":"10.1002\/14651858.CD002819.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD002819.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD002819.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1567-5769(02)00268-0","article-title":"High-dose cyclophosphamide in multiple sclerosis patients undergoing autologous stem cell transplantation","volume":"3","author":"McGuire","year":"2003","journal-title":"International Immunopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD002819.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/oxfordjournals.bmb.a071393","article-title":"Diagnosis and classification of multiple sclerosis [Review]","volume":"33","author":"McDonald","year":"1977","journal-title":"British Medical Bulletin"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.44.1.16","article-title":"The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial","volume":"44","author":"Noseworthy","year":"1994","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/0090-1229(74)90063-4","article-title":"Experimental allergic encephalomyelitis in cyclophosphamide-treated Lewis rats. Clinical remissions and relapse and effect of treatment in neuro-fibrin deposits","volume":"2","author":"Paterson","year":"1974","journal-title":"Clinical Immunologic Immunopathology"},{"issue":"3","key":"10.1002\/14651858.CD002819.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1191\/1352458502ms845oa","article-title":"Multiple sclerosis Functional Composite : a new measure for clinical outcome in multiple sclerosis","volume":"8","author":"Rudick","year":"2002","journal-title":"Multiple sclerosis"},{"issue":"3","key":"10.1002\/14651858.CD002819.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000113376","article-title":"Emerging treatments in Multiple Sclerosis [Review]","volume":"38","author":"Schluep","year":"1997","journal-title":"European Neurology"},{"issue":"1","key":"10.1002\/14651858.CD002819.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1378\/chest.99.1.143","article-title":"Pulmonary complications of combination therapy with cyclophosphamide and prednisone","volume":"99","author":"Sen","year":"1991","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-124-5-199603010-00003","article-title":"Cyclophosphamide-induced cystitits and bladder cancer in patients with Wegener granulomatosis","volume":"124","author":"Talar-Williams","year":"1996","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1191\/1352458502ms846ed","article-title":"Developing clinical outcome measures in multiple sclerosis: an evolving process","volume":"8","author":"Thompson","year":"2002","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD002819.pub2-BIB0115|cit115","first-page":"283","article-title":"Double-blind study of true vs sham plasmapheresis in patients treated with immunosuppression for acute attacks of multiple sclerosis","volume":"337","author":"Weiner","year":"1990","journal-title":"Progress in clinical and biological research."},{"issue":"2","key":"10.1002\/14651858.CD002819.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1191\/1352458502ms790oa","article-title":"Treatment of multiple sclerosis with cyclophosphamide: critical review and immunologic effects","volume":"8","author":"Weiner","year":"2002","journal-title":"Multiple sclerosis"},{"issue":"3","key":"10.1002\/14651858.CD002819.pub2-BIB0117|cit117","first-page":"188","article-title":"Late results of the treatment of the chronic progressive form of multiple sclerosis with cyclophosphamide and ACTH","volume":"23","author":"Wender","year":"1989","journal-title":"Neurologia i Neurochirurgia Polska"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD002819.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:08:38Z","timestamp":1765757318000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD002819.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2007,1,24]]},"references-count":117,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2009,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002819.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,24]]}}}